Side-by-side · Research reference
DihexavsGHRP-2
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED7/28 cited
BPhase 2HUMAN-REVIEWED15/42 cited
Dihexa
Angiotensin IV Analogue · Pre-Clinical
Not established — animal studies only
GHRP-2
Hexapeptide GHRP · Phase 2 (clinical diagnostic)
SQ · Multiple sites · 1–3×/day
01Mechanism of Action
Parameter
Dihexa
GHRP-2
Primary target
c-Met receptor (HGF receptor tyrosine kinase)
Ghrelin receptor (GHS-R1a) on anterior pituitaryBowers 1990
Pathway
HGF/c-Met receptor activation → downstream signaling cascade → synaptogenesis and dendritic arborization
GHS-R1a → Gαq → Ca²⁺ → GH vesicle exocytosisBowers 2002
Downstream effect
Induction of dendritic arborization, synapse formation, neurogenesis, and neuroprotection in rodent models
Strong GH pulse + IGF-1 elevation; appetite increase via ghrelin agonismBowers 2002
Feedback intact?
—
Yes, with somatostatin feedback active
Origin
Small-molecule angiotensin IV analogue designed to activate HGF/c-Met systemWright 2015
Synthetic hexapeptide; developed by Bowers/Tulane group in the 1980sBowers 1990
Antibody development
—
—
02Dosage Protocols
Parameter
Dihexa
GHRP-2
Human dosing
Not established — no human trials
—
Animal studies
Mouse/rat models only — dosing not translatable to humans
—
Clinical status
No Phase 1, 2, or 3 trials published
—
Frequency
—
1–3× per day
Lower / starter dose
—
50 mcg per dose
Duration
—
8–12 weeks on / 4 off (anecdotal)
Reconstitution
—
Bacteriostatic water
Timing
—
Pre-sleep + fasted preferred
04Side Effects & Safety
Parameter
Dihexa
GHRP-2
Human safety data
None available — no human clinical trials
—
Theoretical c-Met risks
c-Met receptor activation has been implicated in tumorigenesis; unknown cancer risk profile
—
Pre-clinical tolerability
Not systematically reported in available studies
—
Prolactin elevation
—
Mild but measurable
Hunger
—
Strong appetite increase
Injection site reaction
—
Mild erythema
IGF-1 elevation
—
Strong; monitor with chronic high-dose use
Cancer risk
—
Contraindicated in active malignancy
Pregnancy / OB
—
Avoid
Absolute Contraindications
Dihexa
- ·Not approved for human use — research compound only
GHRP-2
- ·Active malignancy
- ·Pregnancy / breastfeeding
Relative Contraindications
Dihexa
- ·Theoretical contraindication: active or history of malignancy (c-Met pathway involvement in cancer)
GHRP-2
- ·Untreated diabetes
05Administration Protocol
Parameter
Dihexa
GHRP-2
1. Human administration
No established protocol. Dihexa has not been tested in human subjects. Animal studies used various routes (typically subcutaneous or intraperitoneal in rodents) not translatable to clinical use.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
2. Legal status
Pre-clinical research compound. Not approved by FDA or any regulatory authority for human use.
SQ — abdomen or thigh. Rotate sites.
3. Timing
—
Pre-sleep + fasted preferred.
4. Storage
—
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Dihexa
— no documented stacks
GHRP-2
+ CJC-1295 (no DAC)
StrongGHRP-2 + CJC-1295-no-DAC is a higher-amplitude alternative to the ipamorelin + CJC-1295 stack. GHRP-2 produces a stronger pulse but with cortisol + prolactin signal — choose when maximum GH amplitude is the goal and the side-effect tolerance is acceptable.
- GHRP-2
- 100–200 mcg SQ · pre-sleep
- CJC-1295 (no DAC)
- 100 mcg SQ · same injection
- Primary benefit
- High-amplitude GH pulse, body composition